This article is a correction to:
Efficacy and Safety of Adherence to dl-3-n-Butylphthalide Treatment in Patients With Non-disabling Minor Stroke and TIA—Analysis From a Nationwide, Multicenter Registry
Zefeng Tan1,2
Yin Zhao1
Wanyong Yang1Shenwen He2
Yan Ding1
Anding Xu1* on behalf of the BRIDGE trial Investigators- 1Department of Neurology, the First Affiliated Hospital, Jinan University, Guangzhou, China
- 2Department of Neurology, Shun De Hospital of Jinan University, Guangzhou, China
by Tan, Z., Zhao, Y., Yang, W., He, S., Ding, Y., and Xu, A. (2021). Front. Neurol. 12:720664. doi: 10.3389/fneur.2021.720664
In the original article, there was an error. The Results section contained an error regarding the number of subjects in the compliance and non-compliance NBP groups. The number of non-compliance patients was mistakenly listed as the number of compliance patients in the results section. Also, the number of patients in the non-compliance group was taken as the number of patients in the compliance group.
A correction has been made to Results, paragraph 1, lines 8 to 12, page 3.
A total of 2,966 cases were entered into the analytical dataset based on the definition of the analytical dataset (Supplementary Figure 1), of which there were 1,042 cases in the NBP-compliance group and 1,924 cases in the NBP-non-compliance group.
In the original article, there was an error. The second error is related to subgroup analysis. There was a discrepancy between the subgroup analyses described in this article and those shown in Table 3 of NIHSS0-2 and NIHSS3-5. Our initial statistical analysis section contained an error related to our subgroup analysis, which we corrected, and then updated our table, but we did not update the Abstract and Subgroup Analysis sections.
A correction has been made to the Abstract, Results, lines 10 to 11.
…[88.82 vs. 76.21%, adjusted odds ratio 2.52 (1.81–3.50), adjusted interaction P = 0.00].
A correction has been made to Subgroup Analysis, lines 5 to 7, page 4.
…subgroup (88.82%, 453 cases) than in the NIHSS (0–2) subgroup (95.20%, 496 cases) (OR = 2.52, 95% CI, 1.81–3.50, and interaction p = 0.00).
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: minor stroke, dl-3-n-butylphthalide, TIA, efficacy, modified rankin scale, non-disabling
Citation: Tan Z, Zhao Y, Yang W, He S, Ding Y and Xu A (2021) Corrigendum: Efficacy and Safety of Adherence to dl-3-n-Butylphthalide Treatment in Patients With Non-disabling Minor Stroke and TIA—Analysis From a Nationwide, Multicenter Registry. Front. Neurol. 12:800494. doi: 10.3389/fneur.2021.800494
Received: 23 October 2021; Accepted: 29 October 2021;
Published: 23 November 2021.
Edited and reviewed by: Jean-Claude Baron, University of Cambridge, United Kingdom
Copyright © 2021 Tan, Zhao, Yang, He, Ding and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Anding Xu, tlil@jnu.edu.cn